NCT03457649View on ClinicalTrials.gov

IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

September 9, 2015

Primary Completion Date

November 15, 2016

Study Completion Date

February 21, 2017

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

ARGX-113

BIOLOGICAL

Placebo

Sponsors

Lead Sponsor

argenx
All Listed Sponsors
lead

argenx

INDUSTRY